Biocryst Pharmaceuticals (BCRX) Gains from Investment Securities (2010 - 2026)

Biocryst Pharmaceuticals has reported Gains from Investment Securities for 16 years, with the latest figure at $1.4 million in Q1 2026.

• For the quarter ending Q1 2026, Gains from Investment Securities rose 143000.0% year-over-year to $1.4 million; the trailing twelve-month figure through Mar 2026 stood at $10.3 million (up 98.17% YoY), and the FY2025 full-year result was $8.8 million, up 17.41% from the prior year.
• Gains from Investment Securities for Q1 2026 stood at $1.4 million, down from $7.3 million in the prior quarter.
• The five-year high for Gains from Investment Securities was $7.5 million in Q4 2024, with the low at -$4.2 million in Q3 2024.
• Historically, Gains from Investment Securities has averaged $1.8 million across 4 years, with a median of $1.2 million in 2025.
• Annual changes were most pronounced in 2025 — Gains from Investment Securities tumbled 99.96% — and 2026, when it soared 143000.0%.
• Biocryst Pharmaceuticals' Gains from Investment Securities stood at $58000.0 in 2022, then soared by 12891.38% to $7.5 million in 2024, then retreated by 3.36% to $7.3 million in 2025, then plunged by 80.35% to $1.4 million in 2026.
• The last three Gains from Investment Securities figures came in at $1.4 million (Q1 2026), $7.3 million (Q4 2025), and $513000.0 (Q3 2025), per Business Quant data.